NCT05703646 (e-Yukon) is a clinical trial in Ischemic Heart Disease, sponsored by Translumina GmbH.

Who is sponsoring NCT05703646?

NCT05703646 is sponsored by Translumina GmbH.

What condition does NCT05703646 study?

NCT05703646 studies Ischemic Heart Disease.

Is NCT05703646 still recruiting?

NCT05703646 is currently status unknown. Last updated 27 November 2023.

Last reviewed 2023-11-27 · How we verify

NCT05703646: e-Yukon

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Clinical Performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Stents in Routine Practice

Status unknown Last updated 27 November 2023

What this trial tests

trial in Ischemic Heart Disease in 5,000 participants. Status unknown.

Timeline

30 March 2023

Primary endpoint
30 March 2026

30 March 2026

Quick facts

Lead sponsor	Translumina GmbH
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	30 March 2023
Primary completion	30 March 2026
Estimated completion	30 March 2026
Sites	1 location across United Arab Emirates

Conditions studied

Ischemic Heart Disease — all drugs for Ischemic Heart Disease →

Sponsor

Translumina GmbH

Who can join

Adults 18 to 80, any sex, with Ischemic Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to collect safety and performance information in the setting of a large-scale clinical registry. Patients meeting the selection criteria will be included, in chronological order of their implantation. This registry does not require any additional procedures, follow-up interventions, or ionizing radiation for patients. The inclusion period is planned to last 2 years, starting in Q1 2023. The study will be complete when data on all patient's follow-up for one year have been collected.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ischemic Heart Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT06712862 — A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR · recruiting
NCT07009418 — Smart Angioplasty Research Team-Coronary CT Angiography Versus Standard Care as Follow-up Strategies in High-Risk Patien · NA · recruiting
NCT06891456 — Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia · NA · recruiting

Other Translumina GmbH trials

Trials by the same sponsor.

NCT06420505 — Evaluation of the Vivo Isar Stent System in Routine Clinical Practice · recruiting
NCT03918070 — Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05703646 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Translumina GmbH
Last refreshed: 27 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05703646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing